{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:35:13Z","timestamp":1791308113428,"version":"4.3.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T00:00:00Z","timestamp":1366848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s12026-013-8422-y","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T10:49:17Z","timestamp":1367405357000},"page":"477-491","source":"Crossref","is-referenced-by-count":142,"title":["Complement and autoimmunity"],"prefix":"10.1007","volume":"56","author":[{"given":"Eleonora","family":"Ballanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ballanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"key":"8422_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF01837364","volume":"15","author":"MC Moffitt","year":"1994","unstructured":"Moffitt MC, Frank MM. Complement resistance in microbes. Springer Semin Immunopathol. 1994;15:327\u201344.","journal-title":"Springer Semin Immunopathol"},{"key":"8422_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.imlet.2004.11.010","volume":"97","author":"BP Morgan","year":"2005","unstructured":"Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett. 2005;97:171\u20139.","journal-title":"Immunol Lett"},{"key":"8422_CR3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058\u201366.","journal-title":"N Engl J Med"},{"key":"8422_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2005.06.028","volume":"43","author":"H Hawlisch","year":"2006","unstructured":"Hawlisch H, K\u00f6hl J. Complement and toll-like receptors: key regulators of adaptive immune responses. Mol Immunol. 2006;43:13\u201321.","journal-title":"Mol Immunol"},{"key":"8422_CR5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140\u20134.","journal-title":"N Engl J Med"},{"key":"8422_CR6","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.4049\/jimmunol.173.5.3044","volume":"173","author":"AJ Nauta","year":"2004","unstructured":"Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol. 2004;173:3044\u201350.","journal-title":"J Immunol"},{"key":"8422_CR7","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.molimm.2009.04.026","volume":"46","author":"P G\u00e1l","year":"2009","unstructured":"G\u00e1l P, Dob\u00f3 J, Z\u00e1vodszky P, Sim RB. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol Immunol. 2009;46:2745\u201352.","journal-title":"Mol Immunol"},{"key":"8422_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1385\/IR:33:2:103","volume":"33","author":"H Rus","year":"2005","unstructured":"Rus H, Cudrici C, Niculescu F. The role of the complement system in innate immunity. Immunol Res. 2005;33:103\u201312.","journal-title":"Immunol Res"},{"key":"8422_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-2776(08)60868-8","volume":"61","author":"MK Liszewski","year":"1996","unstructured":"Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol. 1996;61:201\u201383.","journal-title":"Adv Immunol"},{"key":"8422_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0952-7915(99)00049-7","volume":"12","author":"G Lindahl","year":"2000","unstructured":"Lindahl G, Sj\u00f6bring U, Johnsson E. Human complement regulators: a major target for pathogenic microorganisms. Curr Opin Immunol. 2000;12:44\u201351.","journal-title":"Curr Opin Immunol"},{"key":"8422_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2004.05.007","volume":"114","author":"AE Davis","year":"2005","unstructured":"Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3\u20139.","journal-title":"Clin Immunol"},{"key":"8422_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1040-8428(99)00052-9","volume":"33","author":"P Boccuni","year":"2000","unstructured":"Boccuni P, Del Vecchio L, Di Noto R, Rotoli B. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crit Rev Oncol Hematol. 2000;33:25\u201343.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8422_CR13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000079261","volume":"134","author":"AJ Nauta","year":"2004","unstructured":"Nauta AJ, Roos A, Daha MR. A regulatory role for complement in innate immunity and autoimmunity. Int Arch Allergy Immunol. 2004;134:310\u201323.","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl B","key":"8422_CR14","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0828-282X(06)70982-5","volume":"22","author":"P Th\u00e9roux","year":"2006","unstructured":"Th\u00e9roux P, Martel C. Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol. 2006;22(Suppl B):18B\u201324B.","journal-title":"Can J Cardiol"},{"key":"8422_CR15","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-58753-5","volume-title":"The complement system","author":"KO Rother","year":"1998","unstructured":"Rother KO, Till GO, Hansch GM. The complement system. 2nd ed. Berlin: Springer; 1998.","edition":"2"},{"key":"8422_CR16","volume-title":"Experimental Immunochemistry","author":"EA Kabat","year":"1961","unstructured":"Kabat EA, Mayer MM. Experimental Immunochemistry. 2nd ed. Springfield, IL: Thomas; 1961.","edition":"2"},{"key":"8422_CR17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keh719","volume":"44","author":"G Sturfelt","year":"2005","unstructured":"Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology. 2005;44:1227\u201332.","journal-title":"Rheumatology"},{"key":"8422_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-1759(90)90358-3","volume":"133","author":"M Oppermann","year":"1990","unstructured":"Oppermann M, Baumgarten H, Brandt E, Gottsleben W, Kurts C, G\u00f6tze O. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods. 1990;133:181\u201390.","journal-title":"J Immunol Methods"},{"key":"8422_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0022-1759(88)90133-0","volume":"111","author":"A Klos","year":"1988","unstructured":"Klos A, Ihrig V, Messner M, Grabbe J, Bitter-Suermann D. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods. 1988;111:241\u201352.","journal-title":"J Immunol Methods"},{"key":"8422_CR20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-1759(93)90160-9","volume":"159","author":"J Seino","year":"1993","unstructured":"Seino J, Warmold A, Wall Bake Lvd, van Es LA, Daha MR. A novel ELISA assay for the detection of C3 nephritic factor. J Immunol Methods. 1993;159:221\u20137.","journal-title":"J Immunol Methods"},{"key":"8422_CR21","volume-title":"Autoantibodies","author":"Y Shoenfeld","year":"2007","unstructured":"Shoenfeld Y, Gershwin ME, Meroni PL. Autoantibodies. 2nd ed. Amsterdam: Elsevier; 2007.","edition":"2"},{"key":"8422_CR22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-4614-4118-2_19","volume":"734","author":"JM Thurman","year":"2013","unstructured":"Thurman JM, Rohrer B. Noninvasive detection of complement activation through radiologic imaging. Adv Exp Med Biol. 2013;734:271\u201382.","journal-title":"Adv Exp Med Biol"},{"key":"8422_CR23","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","volume":"34","author":"M Chen","year":"2010","unstructured":"Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276\u201386.","journal-title":"J Autoimmun"},{"key":"8422_CR24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","volume":"1173","author":"HD Pettigrew","year":"2009","unstructured":"Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance of complement deficiencies. Ann N Y Acad Sci. 2009;1173:108\u201323.","journal-title":"Ann N Y Acad Sci"},{"key":"8422_CR25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1568-9972(03)00052-1","volume":"2","author":"A Etzioni","year":"2003","unstructured":"Etzioni A. Immune deficiency and autoimmunity. Autoimmun Rev. 2003;2:364\u20139.","journal-title":"Autoimmun Rev"},{"key":"8422_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0753-3322(03)00084-2","volume":"57","author":"SA Boackle","year":"2003","unstructured":"Boackle SA. Complement and autoimmunity. Biomed Pharmacother. 2003;57:269\u201373.","journal-title":"Biomed Pharmacother"},{"key":"8422_CR27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2008.11.004","volume":"8","author":"G Bussone","year":"2009","unstructured":"Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev. 2009;8:332\u20136.","journal-title":"Autoimmun Rev"},{"key":"8422_CR28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1568-9972(02)00032-0","volume":"1","author":"V Pittoni","year":"2002","unstructured":"Pittoni V, Valesini G. The clearance of apoptotic cells: implications for autoimmunity. Autoimmun Rev. 2002;1:154\u201361.","journal-title":"Autoimmun Rev"},{"key":"8422_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/cmi.2008.2","volume":"5","author":"JH Lu","year":"2008","unstructured":"Lu JH, Teh BK, Wang L, Wang YN, Tan YS, Lai MC, et al. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol. 2008;5:9\u201321.","journal-title":"Cell Mol Immunol"},{"key":"8422_CR30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","volume":"74","author":"MC Carroll","year":"2000","unstructured":"Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol. 2000;74:61\u201388.","journal-title":"Adv Immunol"},{"key":"8422_CR31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/08916930701510673","volume":"40","author":"L Truedsson","year":"2007","unstructured":"Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40:560\u20136.","journal-title":"Autoimmunity"},{"key":"8422_CR32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2010.08.015","volume":"10","author":"LE Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz LE, Janko C, Schulze C, Schorn C, Sarter K, Schett G, et al. Autoimmunity and chronic inflammation\u2014two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev. 2010;10:38\u201342.","journal-title":"Autoimmun Rev"},{"key":"8422_CR33","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.molimm.2007.02.014","volume":"44","author":"E Csomor","year":"2007","unstructured":"Csomor E, Bajtay Z, S\u00e1ndor N, Krist\u00f3f K, Arlaud GJ, Thiel S, et al. Complement protein C1q induces maturation of human dendritic cells. Mol Immunol. 2007;44:3389\u201397.","journal-title":"Mol Immunol"},{"key":"8422_CR34","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.4049\/jimmunol.1103760","volume":"188","author":"ME Benoit","year":"2012","unstructured":"Benoit ME, Clarke EV, Morgado P, Fraser DA, Tenner AJ. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J Immunol. 2012;188:5682\u201393.","journal-title":"J Immunol"},{"key":"8422_CR35","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/j.molimm.2009.05.181","volume":"46","author":"A Erdei","year":"2009","unstructured":"Erdei A, Isa\u00e1k A, T\u00f6r\u00f6k K, S\u00e1ndor N, Kremlitzka M, Prechl J, et al. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol Immunol. 2009;46:2767\u201373.","journal-title":"Mol Immunol"},{"key":"8422_CR36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.1995.tb02277.x","volume":"101","author":"HV Marquart","year":"1995","unstructured":"Marquart HV, Svendsen A, Rasmussen JM, Nielsen CH, Junker P, Svehag SE, et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1995;101:60\u20135.","journal-title":"Clin Exp Immunol"},{"key":"8422_CR37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/art.1780290606","volume":"29","author":"JG Wilson","year":"1986","unstructured":"Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b\/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 1986;29:739\u201347.","journal-title":"Arthritis Rheum"},{"key":"8422_CR38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clim.2010.08.006","volume":"137","author":"KE Prokopec","year":"2010","unstructured":"Prokopec KE, Rhodiner M, Matt P, Lindqvist U, Kleinau S. Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis. Clin Immunol. 2010;137:322\u20139.","journal-title":"Clin Immunol"},{"key":"8422_CR39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2010.09.007","volume":"10","author":"R Gualtierotti","year":"2010","unstructured":"Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10:3\u20137.","journal-title":"Autoimmun Rev"},{"key":"8422_CR40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431\u201356.","journal-title":"Annu Rev Immunol"},{"key":"8422_CR41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","volume":"76","author":"MC Pickering","year":"2000","unstructured":"Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency and apoptosis. Adv Immunol. 2000;76:227\u2013324.","journal-title":"Adv Immunol"},{"key":"8422_CR42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJM198202043060503","volume":"306","author":"G Biesecker","year":"1982","unstructured":"Biesecker G, Lavin L, Ziskind M, Koffler D. Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med. 1982;306:264\u201370.","journal-title":"N Engl J Med"},{"key":"8422_CR43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0190-9622(93)70093-9","volume":"28","author":"KF Helm","year":"1993","unstructured":"Helm KF, Peters MS. Deposition of membrane attack complex in cutaneous lesions of lupus erythematosus. J Am Acad Dermatol. 1993;28:687\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"8422_CR44","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1172\/JCI105272","volume":"44","author":"F Paronetto","year":"1965","unstructured":"Paronetto F, Koffler D. Immunofluorescent localization of immunoglobulins, complement, and fibrinogen in human diseases. I. Systemic lupus erythematosus. J Clin Invest. 1965;44:1657\u201364.","journal-title":"J Clin Invest"},{"key":"8422_CR45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.115.1.63","volume":"115","author":"PJ Lachmann","year":"1962","unstructured":"Lachmann PJ, Muller-Eberhard HJ, Kunkel HG, Paronetto F. The localization of in vivo bound complement in tissue section. J Exp Med. 1962;115:63\u201382.","journal-title":"J Exp Med"},{"key":"8422_CR46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2012.03.009","volume":"12","author":"S Sciascia","year":"2012","unstructured":"Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev. 2012;12:157\u201363.","journal-title":"Autoimmun Rev"},{"issue":"Suppl 3","key":"8422_CR47","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1186\/ar586","volume":"4","author":"MJ Walport","year":"2002","unstructured":"Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4(Suppl 3):S279\u201393.","journal-title":"Arthritis Res"},{"key":"8422_CR48","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4049\/jimmunol.135.3.2005","volume":"135","author":"GD Ross","year":"1985","unstructured":"Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, et al. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and\/or complement activation. J Immunol. 1985;135:2005\u201314.","journal-title":"J Immunol"},{"key":"8422_CR49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2011.04.012","volume":"10","author":"E Ballanti","year":"2011","unstructured":"Ballanti E, Perricone C, Di Muzio G, Kroegler B, Chimenti MS, Graceffa D, et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10:617\u201323.","journal-title":"Autoimmun Rev"},{"key":"8422_CR50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","volume":"146","author":"DE Trentham","year":"1977","unstructured":"Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977;146:857\u201368.","journal-title":"J Exp Med"},{"key":"8422_CR51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","volume":"283","author":"JS Courtenay","year":"1980","unstructured":"Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283:666\u20138.","journal-title":"Nature"},{"key":"8422_CR52","first-page":"26","volume":"54","author":"ES Cathcart","year":"1986","unstructured":"Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C. Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab Invest. 1986;54:26\u201331.","journal-title":"Lab Invest"},{"key":"8422_CR53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.168.2.777","volume":"168","author":"TJ Yoo","year":"1988","unstructured":"Yoo TJ, Kim SY, Stuart JM, Floyd RA, Olson GA, Cremer MA, et al. Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med. 1988;168:777\u201382.","journal-title":"J Exp Med"},{"key":"8422_CR54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4049\/jimmunol.169.1.454","volume":"169","author":"MA Hietala","year":"2002","unstructured":"Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol. 2002;169:454\u20139.","journal-title":"J Immunol"},{"key":"8422_CR55","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","volume":"92","author":"Y Wang","year":"1995","unstructured":"Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA. 1995;92:8955\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8422_CR56","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/092986706777441959","volume":"13","author":"M Mizuno","year":"2006","unstructured":"Mizuno M. A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. Curr Med Chem. 2006;13:1707\u201317.","journal-title":"Curr Med Chem"},{"key":"8422_CR57","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/ard.51.11.1254","volume":"51","author":"D D\u2019Cruz","year":"1992","unstructured":"D\u2019Cruz D, Taylor J, Ahmed T, Asherson R, Khamashta M, Hughes GR. Complement factor 2 deficiency: a clinical and serological family study. Ann Rheum Dis. 1992;51:1254\u20136.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/039463201102400209","volume":"24","author":"G Muzio Di","year":"2011","unstructured":"Di Muzio G, Perricone C, Ballanti E, Kroegler B, Greco E, Novelli L, et al. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol. 2011;24:357\u201366.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"8422_CR59","doi-asserted-by":"crossref","first-page":"7298","DOI":"10.1016\/S0021-9258(18)48236-1","volume":"262","author":"N Miura","year":"1987","unstructured":"Miura N, Prentice HL, Scheider PM, Perlmutter DH. Synthesis and regulation of the two human complement C4 genes in stable transfected mouse fibroblasts. J Biol Chem. 1987;262:7298\u2013305.","journal-title":"J Biol Chem"},{"key":"8422_CR60","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/eji.1830170817","volume":"17","author":"T Andus","year":"1988","unstructured":"Andus T, Heinrich PC, Bauer J, Trau-Thi TA, Decker K, Manuel D, et al. Discrimination of hepatocyte stimulating activity from human recombinant tumour necrosis factor a. Eur J lmmunol. 1988;17:1193\u20137.","journal-title":"Eur J lmmunol"},{"key":"8422_CR61","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/eji.1830190809","volume":"19","author":"R Anthony","year":"1989","unstructured":"Anthony R, EL-Omar E, Lappin DF, MacSween RNM, Whaley K. Regulation of hepatic synthesis of C3 and C4 during acute-phase response in the rat. Eur J Immunol. 1989;19:1405\u201312.","journal-title":"Eur J Immunol"},{"key":"8422_CR62","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/eji.1830180817","volume":"18","author":"G Ramadori","year":"1988","unstructured":"Ramadori G, Van Daume J, Riedert H, Mayer Zum Buschenfelde KH. Interleukin-6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse comparison as with interleukin-1\u03b2 and tumour necrosis faclor-\u03b1. Eur J Immunol. 1988;18:1259\u201364.","journal-title":"Eur J Immunol"},{"key":"8422_CR63","first-page":"54","volume":"78","author":"GJ Moffat","year":"1989","unstructured":"Moffat GJ, Lappin D, Birnie GD, Whaley K. Complement biosynthesis in human synovial tissue. Clin Exp Immunol. 1989;78:54\u201360.","journal-title":"Clin Exp Immunol"},{"key":"8422_CR64","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM197406062902304","volume":"290","author":"S Ruddy","year":"1974","unstructured":"Ruddy S, Colten HR. Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med. 1974;290:1284\u20138.","journal-title":"N Engl J Med"},{"key":"8422_CR65","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","volume":"46","author":"E Neumann","year":"2002","unstructured":"Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002;46:934\u201345.","journal-title":"Arthritis Rheum"},{"key":"8422_CR66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00301260","volume":"13","author":"D Guc","year":"1993","unstructured":"Guc D, Gulati P, Lemercier C, Lappin D, Birnie GD, Whaley K. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int. 1993;13:139\u201346.","journal-title":"Rheumatol Int"},{"key":"8422_CR67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0162-3109(92)90014-4","volume":"24","author":"K Whaley","year":"1992","unstructured":"Whaley K, Guc D, Gulati P, Lappin D. Synthesis of complement components by synovial membrane. Immunopharmacology. 1992;24:83\u20139.","journal-title":"Immunopharmacology"},{"key":"8422_CR68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.47.3.190","volume":"47","author":"M Doherty","year":"1988","unstructured":"Doherty M, Richards N, Hornby J, Powell R. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. Ann Rheum Dis. 1988;47:190\u20137.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR69","first-page":"250","volume":"84","author":"DA Oleesky","year":"1991","unstructured":"Oleesky DA, Daniels RH, Williams BD, Amos N, Morgan BP. Terminal complement complexes and C1\/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin Exp Immunol. 1991;84:250\u20135.","journal-title":"Clin Exp Immunol"},{"key":"8422_CR70","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.55.12.888","volume":"55","author":"YT Konttinen","year":"1996","unstructured":"Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis. 1996;55:888\u201394.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.49.10.747","volume":"49","author":"PJ Jose","year":"1990","unstructured":"Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990;49:747\u201352.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR72","first-page":"24","volume":"22","author":"K H\u00f8g\u00e5sen","year":"1995","unstructured":"H\u00f8g\u00e5sen K, Mollnes TE, Harboe M, G\u00f6tze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol. 1995;22:24\u20138.","journal-title":"J Rheumatol"},{"key":"8422_CR73","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI108399","volume":"57","author":"RH Zubler","year":"1976","unstructured":"Zubler RH, Nydegger U, Perrin LH, Fehr K, McCormick J, Lambert PH, et al. Circulating and intra-articular immune complexes in patients with rheumatoid arthritis: correlation of 125IClq binding activity with clinical and biological features of the disease. J Clin Invest. 1976;57:1308\u201319.","journal-title":"J Clin Invest"},{"key":"8422_CR74","first-page":"1","volume":"38","author":"FC Hay","year":"1979","unstructured":"Hay FC, Nineham LJ, Perumal R, Roitt IM. Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis: correlation with clinical features. Ann Rheum Dis. 1979;38:1\u20137.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR75","first-page":"33","volume":"13","author":"DL Robbins","year":"1986","unstructured":"Robbins DL, Fiegal DW Jr, Leek JC, Shapiro R, Wiesner K. Complement activation by 19S IgM rheumatoid factor: relationship to disease activity in rheumatoid arthritis. J Rheumatol. 1986;13:33\u20138.","journal-title":"J Rheumatol"},{"key":"8422_CR76","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/ard.52.11.795","volume":"52","author":"Y Sato","year":"1993","unstructured":"Sato Y, Sato R, Watanabe H, Kogure A, Watanabe K, Nishimaki T, et al. Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors. Ann Rheum Dis. 1993;52:795\u2013800.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF02207676","volume":"14","author":"Y Sato","year":"1995","unstructured":"Sato Y, Watanabe H, Kogure A, Miyata M, Watanabe K, Nishimaki T, et al. Complement-activating properties of IgM rheumatoid factors reacting with IgG subclasses. Clin Rheumatol. 1995;14:425\u20138.","journal-title":"Clin Rheumatol"},{"key":"8422_CR78","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI107949","volume":"55","author":"K Tanimoto","year":"1975","unstructured":"Tanimoto K, Cooper NR, Johnson JS, Vaughan JH. Complement fixation by rheumatoid factor. J Clin Invest. 1975;55:437\u201345.","journal-title":"J Clin Invest"},{"key":"8422_CR79","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.1975.tb36039.x","volume":"256","author":"S Ruddy","year":"1975","unstructured":"Ruddy S, Austen KF. Activation of the complement and properdin systems in rheumatoid arthritis. Ann N Y Acad Sci. 1975;256:96\u2013104.","journal-title":"Ann N Y Acad Sci"},{"key":"8422_CR80","first-page":"453","volume":"7","author":"A El-Ghobarey","year":"1980","unstructured":"El-Ghobarey A, Whaley K. Alternative pathway complement activation in rheumatoid arthritis. J Rheumatol. 1980;7:453\u201360.","journal-title":"J Rheumatol"},{"key":"8422_CR81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nm0395-237","volume":"1","author":"R Malhotra","year":"1995","unstructured":"Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1:237\u201343.","journal-title":"Nat Med"},{"key":"8422_CR82","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.24622","volume":"60","author":"LA Trouw","year":"2009","unstructured":"Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009;60:1923\u201331.","journal-title":"Arthritis Rheum"},{"key":"8422_CR83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1749-6632.1982.tb22140.x","volume":"389","author":"JE Volonakis","year":"1982","unstructured":"Volonakis JE. Complement activation by C-reactive protein complexes. Ann N Y Acad Sci. 1982;389:235\u201349.","journal-title":"Ann N Y Acad Sci"},{"key":"8422_CR84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4049\/jimmunol.157.1.473","volume":"157","author":"GJ Wolbink","year":"1996","unstructured":"Wolbink GJ, Brouwer MC, Buysman S, ten Berge IJM, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157:473\u20139.","journal-title":"J Immunol"},{"key":"8422_CR85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1086\/513803","volume":"177","author":"GJ Wolbink","year":"1998","unstructured":"Wolbink GJ, Bossink AWJ, Groeneveld ABJ, de Groot MCM, Thijs LG, Hack CE. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis. 1998;177:81\u20137.","journal-title":"J Infect Dis"},{"key":"8422_CR86","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1529-0131(200105)44:5<997::AID-ANR178>3.0.CO;2-C","volume":"44","author":"ET Molenaar","year":"2001","unstructured":"Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum. 2001;44:997\u20131002.","journal-title":"Arthritis Rheum"},{"key":"8422_CR87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.95.1.97","volume":"95","author":"WK Lagrand","year":"1997","unstructured":"Lagrand WK, Niessen HWM, Wolbink GJ, Jaspers LH, Visser CA, Verheugt FWA, et al. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97\u2013103.","journal-title":"Circulation"},{"key":"8422_CR88","doi-asserted-by":"crossref","first-page":"32301","DOI":"10.1074\/jbc.M504828200","volume":"280","author":"A Sj\u00f6berg","year":"2005","unstructured":"Sj\u00f6berg A, Onnerfjord P, M\u00f6rgelin M, Heineg\u00e5rd D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. 2005;280:32301\u20138.","journal-title":"J Biol Chem"},{"key":"8422_CR89","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/art.1780290603","volume":"29","author":"TE Mollnes","year":"1986","unstructured":"Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986;29:715\u201321.","journal-title":"Arthritis Rheum"},{"key":"8422_CR90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/03009749109103019","volume":"20","author":"U Olmez","year":"1991","unstructured":"Olmez U, Garred P, Mollnes TE, Harboe M, Berntzen HB, Munthe E. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand J Rheumatol. 1991;20:183\u20139.","journal-title":"Scand J Rheumatol"},{"key":"8422_CR91","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.21729","volume":"54","author":"D Wouters","year":"2006","unstructured":"Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q\u2013C4 complexes as novel activation products. Arthritis Rheum. 2006;54:1143\u201350.","journal-title":"Arthritis Rheum"},{"key":"8422_CR92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2230.1990.tb02011.x","volume":"15","author":"EW Rosenberg","year":"1990","unstructured":"Rosenberg EW, Noah PW, Wyatt RJ, Jones RM, Kolb WP. Complement activation in psoriasis. Clin Exp Dermatol. 1990;15:16\u201320.","journal-title":"Clin Exp Dermatol"},{"key":"8422_CR93","first-page":"82","volume":"50","author":"G Partsch","year":"1991","unstructured":"Partsch G, Bauer K, Br\u00f6ll H, Petera P, Dunky A, Mer\u00e9tey K. Complement C3 cleavage product in synovial fluids detected by immunofixation. Z Rheumatol. 1991;50:82\u20135.","journal-title":"Z Rheumatol"},{"key":"8422_CR94","first-page":"225","volume":"21","author":"G Triolo","year":"2003","unstructured":"Triolo G, Accardo-Palumbo A, Sall\u00ec L, Ciccia F, Ferrante A, Tedesco L, et al. Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation. Clin Exp Rheumatol. 2003;21:225\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"8422_CR95","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/33.7.626","volume":"33","author":"D Rivas","year":"1994","unstructured":"Rivas D, Riestra-Noriega JL, Torre-Alonso JC, Rodriguez A, Guti\u00e9rrez C. Decrease in detectable complement receptor type 1 levels on erythrocytes from patients with psoriatic polyarthritis. Br J Rheumatol. 1994;33:626\u201330.","journal-title":"Br J Rheumatol"},{"key":"8422_CR96","first-page":"23","volume":"30","author":"MS Chimenti","year":"2012","unstructured":"Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30:23\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"8422_CR97","author":"MS Chimenti","year":"2012","unstructured":"Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2012;. doi: 10.1016\/j.autrev.2012.10.002 .","journal-title":"Autoimmun Rev"},{"key":"8422_CR98","first-page":"337","volume":"120","author":"AS Townes","year":"1967","unstructured":"Townes AS. Topics in clinical medicine. Complement\u2019s levels in disease. Johns Hopkins Med J. 1967;120:337\u20139.","journal-title":"Johns Hopkins Med J"},{"key":"8422_CR99","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/anr.1780321011","volume":"32","author":"G Senaldi","year":"1989","unstructured":"Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum. 1989;32:1262\u20137.","journal-title":"Arthritis Rheum"},{"key":"8422_CR100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"8422_CR101","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.60.6.592","volume":"60","author":"G Valentini","year":"2001","unstructured":"Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D\u2019Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592\u20138.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR102","first-page":"1","volume":"34","author":"M Hudson","year":"2007","unstructured":"Hudson M, Walker JG, Fritzler M, Taillefer S, Canadian Scleroderma Research Group, Baron M. Hypocomplementemia in systemic sclerosis, clinical and serological correlations. J Rheumatol. 2007;34:1\u20136.","journal-title":"J Rheumatol"},{"key":"8422_CR103","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0952-7915(95)80028-X","volume":"7","author":"RA Wetsel","year":"1995","unstructured":"Wetsel RA. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol. 1995;7:48\u201353.","journal-title":"Curr Opin Immunol"},{"key":"8422_CR104","first-page":"123","volume":"4","author":"ML Shin","year":"1996","unstructured":"Shin ML, Rus HG, Nicolescu FI. Membrane attack by complement: assembly and biology of terminal complement complexes. Biomembranes. 1996;4:123\u201349.","journal-title":"Biomembranes"},{"key":"8422_CR105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","volume":"195","author":"VM Holers","year":"2002","unstructured":"Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211\u201320.","journal-title":"J Exp Med"},{"key":"8422_CR106","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","volume":"112","author":"G Girardi","year":"2003","unstructured":"Girardi G, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644\u201354.","journal-title":"J Clin Invest"},{"key":"8422_CR107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.181.1.151","volume":"181","author":"YU Kim","year":"1995","unstructured":"Kim YU, Kinoshita H, Molina H, Hourcade D, Esya L, Wagner M, et al. Mouse complement regulatory protein Crry\/p65 utilizes the specific mechanisms of both decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995;181:151\u20139.","journal-title":"J Exp Med"},{"key":"8422_CR108","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.287.5452.498","volume":"287","author":"C Xu","year":"2000","unstructured":"Xu C, Mao D, Holers VM, Palanca B, Cheng A, Molina H. A critical role for the murine complement regulator Crry in fetomaternal tolerance. Science. 2000;287:498\u2013501.","journal-title":"Science"},{"key":"8422_CR109","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1681\/ASN.V94590","volume":"9","author":"M Nangaku","year":"1998","unstructured":"Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol. 1998;9:590\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"8422_CR110","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","volume":"52","author":"SS Pierangeli","year":"2005","unstructured":"Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120\u20134.","journal-title":"Arthritis Rheum"},{"key":"8422_CR111","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2007.02.007","volume":"77","author":"JE Salmon","year":"2008","unstructured":"Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol. 2008;77:51\u20136.","journal-title":"J Reprod Immunol"},{"key":"8422_CR112","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","volume":"68","author":"K Oku","year":"2009","unstructured":"Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009;68:1030\u20135.","journal-title":"Ann Rheum Dis"},{"key":"8422_CR113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","volume":"11","author":"MC Dalakas","year":"2012","unstructured":"Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012;11:203\u20136.","journal-title":"Autoimmun Rev"},{"key":"8422_CR114","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"8422_CR115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314:329\u201334.","journal-title":"N Engl J Med"},{"key":"8422_CR116","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archderm.1995.01690240040007","volume":"131","author":"JM Mascar\u00f3 Jr","year":"1995","unstructured":"Mascar\u00f3 JM Jr, Hausmann G, Herrero C, Grau JM, Cid MC, Palou J, et al. Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol. 1995;131:1386\u201392.","journal-title":"Arch Dermatol"},{"key":"8422_CR117","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI. Sj\u00f6gren\u2019s syndrome. Lancet. 2005;366:321\u201331.","journal-title":"Lancet"},{"key":"8422_CR118","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","volume":"29","author":"FN Skopouli","year":"2000","unstructured":"Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren\u2019s syndrome. Semin Arthritis Rheum. 2000;29:296\u2013304.","journal-title":"Semin Arthritis Rheum"},{"key":"8422_CR119","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","volume":"46","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren\u2019s syndrome. Arthritis Rheum. 2002;46:741\u20137.","journal-title":"Arthritis Rheum"},{"key":"8422_CR120","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","volume":"50","author":"E Theander","year":"2004","unstructured":"Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren\u2019s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262\u20139.","journal-title":"Arthritis Rheum"},{"key":"8422_CR121","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","volume":"44","author":"M Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2005;44:89\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"8422_CR122","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.autrev.2011.08.001","volume":"11","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu\u2019s arteritis: a 2011 update. Autoimmun Rev. 2011;11:61\u20137.","journal-title":"Autoimmun Rev"},{"key":"8422_CR123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjmed.2004.02.030","volume":"117","author":"P Seo","year":"2004","unstructured":"Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117:39\u201350.","journal-title":"Am J Med"},{"key":"8422_CR124","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11926-010-0138-6","volume":"12","author":"CGM Kallenberg","year":"2010","unstructured":"Kallenberg CGM. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep. 2010;12:399\u2013405.","journal-title":"Curr Rheumatol Rep"},{"key":"8422_CR125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","volume":"20","author":"A Schreiber","year":"2009","unstructured":"Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20:289\u201398.","journal-title":"J Am Soc Nephrol"},{"key":"8422_CR126","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52\u201364.","journal-title":"Am J Pathol"},{"key":"8422_CR127","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","volume":"29","author":"GQ Xing","year":"2009","unstructured":"Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29:282\u201391.","journal-title":"J Clin Immunol"},{"key":"8422_CR128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0002-9343(62)90191-2","volume":"32","author":"J Lospalluto","year":"1962","unstructured":"Lospalluto J, Dorward B, Miller W Jr, Ziff M. Cryoglobulinemia based on interaction between a gamma macroglobulin and 7S gamma globulin. Am J Med. 1962;32:142\u20135.","journal-title":"Am J Med"},{"key":"8422_CR129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jcp.55.1.4","volume":"55","author":"C Ferri","year":"2002","unstructured":"Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55:4\u201313.","journal-title":"J Clin Pathol"},{"key":"8422_CR130","first-page":"115","volume":"88","author":"G Monti","year":"1995","unstructured":"Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995;88:115\u201326.","journal-title":"QJM"},{"key":"8422_CR131","first-page":"77","volume":"32","author":"A Tarantino","year":"1978","unstructured":"Tarantino A, Anelli A, Costantino A, De Vecchi A, Monti G, Massaro L. Serum complement pattern in essential mixed cryoglobulinaemia. Clin Exp Immunol. 1978;32:77\u201385.","journal-title":"Clin Exp Immunol"},{"key":"8422_CR132","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2215\/CJN.06710810","volume":"6","author":"JC Davin","year":"2011","unstructured":"Davin JC. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol. 2011;6:679\u201389.","journal-title":"Clin J Am Soc Nephrol"},{"key":"8422_CR133","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.ajkd.2004.10.020","volume":"45","author":"S Hisano","year":"2005","unstructured":"Hisano S, Matsushita M, Fujita T, Iwasaki H. Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis. Am J Kidney Dis. 2005;45:295\u2013302.","journal-title":"Am J Kidney Dis"},{"key":"8422_CR134","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","volume":"17","author":"A Roos","year":"2006","unstructured":"Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724\u201334.","journal-title":"J Am Soc Nephrol"},{"key":"8422_CR135","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ndt\/gfn563","volume":"24","author":"M Espinosa","year":"2009","unstructured":"Espinosa M, Ortega R, G\u00f3mez-Carrasco JM, L\u00f3pez-Rubio F, L\u00f3pez-Andreu M, L\u00f3pez-Oliva MO, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant. 2009;24:886\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"8422_CR136","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1521-6616(03)00034-2","volume":"107","author":"VM Holers","year":"2003","unstructured":"Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003;107:140\u201351.","journal-title":"Clin Immunol"},{"key":"8422_CR137","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0031-6997(24)01349-8","volume":"50","author":"SC Makrides","year":"1998","unstructured":"Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev. 1998;50:59\u201387.","journal-title":"Pharmacol Rev"},{"key":"8422_CR138","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.2741\/asghar","volume":"5","author":"SS Asghar","year":"2000","unstructured":"Asghar SS, Pasch MC. Therapeutic inhibition of the complement system. Y2K update. Front Biosci. 2000;5:E63\u201381.","journal-title":"Front Biosci"},{"key":"8422_CR139","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2000.01129.x","volume":"119","author":"RM Goodfellow","year":"2000","unstructured":"Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol. 2000;119:210\u20136.","journal-title":"Clin Exp Immunol"},{"key":"8422_CR140","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.4049\/jimmunol.166.10.6341","volume":"166","author":"RS Ames","year":"2001","unstructured":"Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001;166:6341\u20138.","journal-title":"J Immunol"},{"key":"8422_CR141","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.10449","volume":"46","author":"TM Woodruff","year":"2002","unstructured":"Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum. 2002;46:2476\u201385.","journal-title":"Arthritis Rheum"},{"key":"8422_CR142","doi-asserted-by":"crossref","first-page":"48921","DOI":"10.1074\/jbc.M302598200","volume":"278","author":"DA Fraser","year":"2003","unstructured":"Fraser DA, Harris CL, Williams AS, Mizuno M, Gallagher S, Smith RA, et al. Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem. 2003;278:48921\u20137.","journal-title":"J Biol Chem"},{"key":"8422_CR143","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","volume":"46","author":"CE Vergunst","year":"2007","unstructured":"Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford). 2007;46:1773\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"8422_CR144","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","volume":"93","author":"Y Wang","year":"1996","unstructured":"Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB\/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA. 1996;93:8563\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8422_CR145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","volume":"164","author":"H Watanabe","year":"2000","unstructured":"Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, et al. Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000;164:786\u201394.","journal-title":"J Immunol"},{"key":"8422_CR146","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.4049\/jimmunol.168.7.3601","volume":"168","author":"L Bao","year":"2002","unstructured":"Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL\/lpr mice. J Immunol. 2002;168:3601\u20137.","journal-title":"J Immunol"},{"key":"8422_CR147","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.ASN.0000051597.27127.A1","volume":"14","author":"L Bao","year":"2003","unstructured":"Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, et al. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL\/lpr mice. J Am Soc Nephrol. 2003;14:670\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"8422_CR148","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.autrev.2011.07.006","volume":"11","author":"G Murdaca","year":"2011","unstructured":"Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11:56\u201360.","journal-title":"Autoimmun Rev"},{"key":"8422_CR149","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/asheducation-2011.1.21","volume":"2011","author":"CJ Parker","year":"2011","unstructured":"Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology Am Soc Hematol Educ Program. 2011;2011:21\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"8422_CR150","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1358\/dot.2010.46.11.1534012","volume":"46","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Zanichelli A. Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today. 2010;46:867\u201374.","journal-title":"Drugs Today"},{"key":"8422_CR151","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3083.1998.00386.x","volume":"48","author":"TE Mollnes","year":"1998","unstructured":"Mollnes TE, H\u00f8g\u00e5sen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol. 1998;48:312\u20137.","journal-title":"Scand J Immunol"},{"key":"8422_CR152","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0161-5890(03)00111-1","volume":"40","author":"BP Morgan","year":"2003","unstructured":"Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol. 2003;40:159\u201370.","journal-title":"Mol Immunol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-013-8422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-013-8422-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-013-8422-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:45:36Z","timestamp":1745999136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-013-8422-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":152,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["8422"],"URL":"https:\/\/doi.org\/10.1007\/s12026-013-8422-y","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}